Promedior Inc.
Formerly Crovela BioPharm, Inc., Medior, Inc.
Funding rounds
3 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Feb 2012 | $22 M | No. 3 | $10 to $50 million | equity, options | SEC | |
| Mar 2010 | $12 M | No. 2 | $10 to $50 million | equity | SEC | |
| Feb 2009 | $6 M | No. 1 | $2 to $10 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Promedior Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2012).
SEC Form D · Mar 2012
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Mar 2012
That is all the official record says: Promedior Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of Promedior Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 11 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Dominick C. Colangelo | Executive officer | Mar 2012 |
| Mark R. Lupher | Executive officer | Mar 2012 |
| Mark H. Lupher | Executive officer | Mar 2010 |
| Dominick C Colangelo | Executive officer | Feb 2009 |
| Amir D. Nashat | Director | Mar 2012 |
| Dominick C. Colangelo | Director | Mar 2012 |
| Geert-Jan D. Mulder | Director | Mar 2012 |
| Hanns A. Pielenz | Director | Mar 2012 |
| Harold R. Werner | Director | Mar 2012 |
| James W. Broderick, M.D. | Director | Mar 2012 |
| John W. Friedman | Director | Mar 2012 |
| Paul D. Goldenheim, M.D. | Director | Mar 2012 |
| Geert-Jan W. Mulder | Director | Mar 2010 |
| James W. Broderick | Director | Mar 2010 |
| John H. Friedman | Director | Mar 2010 |
| Joseph S. Zakrzewski | Director | Mar 2010 |
| Paul D. Goldenheim | Director | Mar 2010 |
| Amir Nashat | Director | Feb 2009 |
| Dominick C Colangelo | Director | Feb 2009 |
| Harold R Werner | Director | Feb 2009 |
| James W Broderick | Director | Feb 2009 |
| Joseph Zakrzewski | Director | Feb 2009 |
| Larry Kauvar | Director | Feb 2009 |
| Paul D Goldenheim | Director | Feb 2009 |